No Data
[Hong Kong Stock Connect] Lai Kai Medicine (02105) fell by 9.29%, with a 15.01% discount for a total of 17.636 million shares issued.
King Wai Financial News | The stock price of Lai Kai Medicine (02105) has fallen. As of the time of publication, it has dropped by 9.29%, to HK$14.26, with a turnover of HK$49.7356 million. On the news front, the company has entered into an agreement with an exclusive placement agent before the trading session today. Accordingly, the company plans to allot a total of 17.636 million shares to no fewer than six placing agents, accounting for approximately 4.52% of the existing issued share capital and approximately 4.33% of the enlarged issued share capital after the completion. The placement price per share is HK$13.36, a discount of 15.01% compared to the closing price of the previous trading day. The total amount raised by the placement is approximately HK$0.236 billion.
【Special Contributor】Deng Shengxing: In the absence of market focus, the market fluctuates between bullish and bearish.
King Wo Finance | The Hang Seng Index closed at 19,705 on Wednesday (20th), up 41 points or 0.2%. The market turnover was 114.6 billion yuan. The National Index rose 0.12%, closing at 7,090, and the Technology Index rose 0.41%, reporting 4,413. Innovent Bio (01801) had its target price raised by ubs group, soaring 8.1% for the day; Lai Kai Pharmaceutical (02105) and eli lilly and co are collaborating on clinical trials for obesity treatment, soaring 48.3% for the day; Bitcoin hit a new high yesterday, with related stock Meitu (01357) rising 10.4%; The Dow Jones Index closed at 43,408 points on Wednesday (20th), up 139 points or 0.32%.
Lai Kai Pharmaceutical (2105.HK) is collaborating with eli lilly and co in the USA to conduct clinical research on the treatment of obesity with the new ActRIIA monoclonal antibody LAE102.
This collaboration will accelerate the global development of LAE102. LAE102 is a novel activin receptor type 2A (ActRIIA) antagonistic monoclonal antibody (mAb) designed for weight loss and muscle maintenance in obese patients. On November 20, 2024, lakai pharmaceutical (2105.HK, a global biomedical technology company focused on the development of new drugs for metabolism and oncology) announced a clinical collaboration with eli lilly and co. This collaboration aims to accelerate lakai pharmaceutical's novel ActRIIA monoclonal antibody LAE102 in the field of obesity treatment.
Citic Securities Acting as Placing Agent for Laekna
Laekna to Use Placement Proceeds for R&D
Kai Medical-B (02105.HK) plans to place a total of 17.636 million shares, raising 0.236 billion HKD.
Glory Holdings reported on November 21 that Kairui Pharmaceutical-B (02105.HK) announced that on November 21, 2024, the company entered into a placement agreement with the exclusive placement agent (namely citic sec), under which the company conditionally agreed to place a total of 17.636 million placement shares to no less than six placers at a price of HKD 13.36 per share through the exclusive placement agent. The placement shares will account for approximately 4.52% of the company's existing issued share capital as of the date of this announcement, and approximately 4.33% of the enlarged issued share capital following completion. The placement shares will be issued and allotted under general authorization, without the need to obtain any shares.
No Data
No Data